Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Pediatr ; 244: 17-23.e1, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-35093318

RESUMO

OBJECTIVE: To determine whether the combination of systemic corticosteroids and nebulized epinephrine, compared with standard care, reduces the duration of positive pressure support in children with bronchiolitis admitted to intensive care. STUDY DESIGN: We performed a pragmatic, multicenter, open-label, randomized trial between July 2013 and November 2019 in children younger than 18 months old with a clinical diagnosis of bronchiolitis. The intervention group received the equivalent of 13 mg/kg prednisolone over 3 days, then 1 mg/kg daily for 3 days, plus 0.05 mL/kg of nebulized 1% epinephrine made up to 6 ml with 0.9% saline via jet nebulizer and mask using oxygen at 12 l/min every 30 minutes for 5 doses, then 1-4 hourly for 3 days, then as required for 3 days. The primary outcome was clinician-managed duration of positive pressure support in intensive care defined as high-flow nasal-prong oxygen, nasopharyngeal continuous positive airway pressure, or mechanical ventilation. RESULTS: In total, 210 children received positive pressure support. In the corticosteroid-epinephrine group, 107 children received positive pressure support for a geometric mean of 26 (95% CI, 22-32) hours compared with 40 (95% CI 34-47) hours in 103 controls, adjusted ratio 0.66 (95% CI 0.51-0.84), P = .001. In the intervention group, 41 (38%) children experienced at least 1 adverse event, compared with 39 (38%) in the control group. CONCLUSIONS: In children with severe bronchiolitis, the duration of clinician-managed pressure support was reduced by regular treatment with systemic corticosteroids and inhaled epinephrine compared with standard care. CLINICAL TRIAL REGISTRATION: Australian Clinical Trials Research Network: ACTRN12613000316707.


Assuntos
Bronquiolite , Corticosteroides/uso terapêutico , Austrália , Bronquiolite/tratamento farmacológico , Criança , Cuidados Críticos , Epinefrina/uso terapêutico , Humanos , Lactente , Oxigênio/uso terapêutico , Solução Salina/uso terapêutico
2.
J Pediatr ; 163(5): 1507-10, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23988135

RESUMO

Infants with congenital heart disease have altered brain development. We characterized cortical folding, a critical part of brain development, in congenital heart disease infants and demonstrated an overall decrease in cortical surface area and cortical folding with regional alterations in the right lateral sulcus and left orbitofrontal region, cingulate region, and central sulcus. These abnormalities were present prior to surgery.


Assuntos
Córtex Cerebral/anormalidades , Cardiopatias Congênitas/fisiopatologia , Cardiopatias Congênitas/cirurgia , Mapeamento Encefálico , Feminino , Lobo Frontal/anormalidades , Giro do Cíngulo/anormalidades , Humanos , Processamento de Imagem Assistida por Computador , Recém-Nascido , Imageamento por Ressonância Magnética , Masculino , Nascimento a Termo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA